Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB versus IBU TAB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB versus IBU TAB 200.
IBU-TAB vs IBU-TAB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
None Documented
None Documented
2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain.
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)